Bahar Özgül, Mehmet Erdem, Ozan Aydemir, Emrah Eliş, Senar Ebinç
Intercontinental Journal of Internal Medicine - 2025;3(4):77-81
Aims: The prevalence of cardiovascular diseases, bone mineral disorders, and anemia in patients undergoing continuous hemodialysis is higher than in the normal population. In addition, due to the ongoing renal parenchymal loss in these patients, there is continuous deterioration in bone mineral metabolism. Anemia, a leading hematological disorder, is considered to be one of the most important and frequent complications leading to compromised quality of life. In this study, we aimed to investigate cardiovascular, bone mineral, and hematological disorders in patients undergoing continuous hemodialysis. Methods: Clinical data of 56 patients receiving continuous hemodialysis at Yüzüncü Yıl University Faculty of Medicine Hospital Nephrology Clinic Dialysis Unit between 01.07.2021 and 01.07.2022 were evaluated retrospectively. Echocardiography), dual-energy X-Ray absorptiometry and laboratory parameters were evaluated for each patient. Demographic characteristics and medications were recorded. Due to the retrospective nature of the study, the sample size was not calculated. Results: The study included 56 patients undergoing hemodialysis, comprising 26 (46.4%) men and 30 (53.6%) women. Mean duration of hemodialysis was 5.55+/-5.09 years. Moreover, 92.9% of the patients were receiving medications, with the most common medications including erythropoiesis-stimulating agents (69.6%), phosphorus binders (48.2%), iron supplements (28.6%), active vitamin D supplements (37.5%), and cinacalcet (12.5%). Cardiovascular diseases were detected in 60.7% of the patients, osteoporosis in 41.1%, and anemia in 78.6%. Conclusion: Cardiovascular disease, bone mineral disorders, and hematological disorders are commonly seen in hemodialysis patients. Hemodialysis patients should be regularly evaluated for complications.
